text:
25th Anniversary of the New York State Network of Occupational Health Clinics Conference
Date:Sep 18 2013From:11:00am to 04:30pmLocation:New York Academy of Medicine, 1216 Fifth Avenue, New York, NY 10029
The Occupational Health Clinical Network, through its 10 regional centers, is a unique statewide effort created to diagnose and prevent occupational disease.The conference will gather health care providers, workers, unions, worker centers and other worker advocates, and employers committed to workplace health safety. The conference will honor the visionaries who played key roles in finding new solutions to the state's high burden of occupational disease. It will also focus on bringing diverse voices together to shape the future of work to reduce the toll of occupational disease on working people in New York State.
Registration Fees
- $50 Residents, Fellows, Students*
- $60 Reduced Rate (for non for profit organizations)*&
- $100 General Attendees (NP, RN, Health and safety, IH, workers, lawyers, union members)
- $200 Practicing Physicians
*Letter of verification from Department Chairman or Chief of Service or copy of badge identification
**Letter of verification from non-profit required
Discounted rooms have been reserved at Courtyard Marriott and will be held until August 6, 2013. For room reservations, please contact the hotel directly. Inform the hotel that you will be attending the 25th Anniversary of the NYS Network of Occupational Health Clinic's Conference.
Courtyard Marriott
410 East 92nd St.
New York, NY 10128
phone: 212-410-6777
Discounted rooms are also available at the Hotel Wales being held until August 5th. Contact the hotel directly,
mentioning #133356/booking number 2350.
Hotel Wales
1295 Madison Avenue (between 92nd & 93rd)
New York, NY 10128
phone: 212-876-6000


text:
VINCENT MICKLE, sometimes calling himself "Hot Vinny," once cruised the Internet with confidence to meet young women whom he eventually entertained in person with alcohol and marijuana. He had sex with one, tried to have sex with others and exchanged nude pictures.
The only problem was that the six young women were very young — ages 14, 15 and 16. In October 2009, Philadelphia police got a tip about Mickle from one of the girls, who became afraid after he showed up at one of her field-hockey games.

subset: commoncrawl


text:
Analytical review of pharma market in Russia
New market research from DSM group, one of Russia's leading market research agencies, shows that despite a background of falling GDP and primary economic indicators for the country, the Russian pharma market in 2009 was able to show growth in ruble terms. The overall value of the pharma market in 2009 amounted to 538 billion rubles (including VAT) in retail prices, 18% higher compared to the previous year. This compares to an overall decline in GDP of -8%.
The Russian pharma market comprises the commercial segment, parapharmaceutical segment and the state-owned medicine segment. Growth was seen across all three with the commercial pharmaceuticals segment growing 22%, driven primarily by price increases, as a result of the higher costs on imported medicines given the weakness of the ruble,the state segment growing by 11% and parapharmaceuticals growing by 15%. Sales for the commercial segment in 2009 were approximately 290 billion rubles ($9.1 billion), sales for the state sector were approximately 133 billion rubles ($4.2 billion), and for parapharmaceuticals were approximately 116 billion rubles ($3.7 billion).
DSM is forecasting the Russian pharmaceutical market will grow by more than 11% in 2010 in ruble terms and by 16% in US dollars to reach a value of $20 billion. More significant growth is expected in 2011 when the hardships of the recent crisis-ridden years have been overcome.
Longer term, DSM forecasts the key drivers for the next 10 years to include:
- Development of the drug reimbursement program
- Introduction of voluntary pharma insurance
- Modernization of the hospital supply programme
- Increase in average drug consumption per capita
In recent years, the government has significantly increased its presence in the Russian pharma market both in terms of financing and legislation initiatives. The share of state medicines in the market in 2009 was approximately 25% and this represents one of most stable segment of the pharma market as its development is funded by the government. The government fulfils its obligations and indexes the reimbursement program. 2009 saw a number of new laws introduced aimed bringing more market regulation to a number of areas including pricing. The government also aims to develop and support local production, including allocating funds to bring production facilities to GMP standards.
In the commercial sector, 2009 saw little significant corporate activity; no M&A deals were made in the retail or distribution segments. Market concentration for the Top 10 companies in the distribution sector has further increased to close 100% in 2009. In both distribution and pharmacy, businesses have been concentrating primarily on increasing the efficiency of existing businesses. In 2010 a «second tide» of pharma business development and retail chain concentration is to be expected.
1. Capacity of Russia's pharmaceutical market
2. Manufacturers
3. Pharmacy chains
4. Distributors
5. Pharmaceutical market growth drivers
DSM Group is the leading marketing agency on the pharmaceutical market in Russia. It is part of the European Society for Opinion and Marketing Research (ESOMAR). The retail audit of the Russian pharmaceutical market conducted by DSM Group is ISO 9001:2000 compliant.
A large-scale study of the Russian pharmaceutical industry backed by regular market monitoring is among the latest implemented projects. The findings of this study are shown in this analytical survey, which encompasses the main trends and all sectors of the pharmaceutical industry, such as manufacturing, distribution, and retail business. The survey report is targeted to international audiences.


text:
Tue 27 Mar 2007
When we are moved to do things …
Posted by Frank DeMarco under Stray Thoughts
1 Comment
When we are moved to do things and don't know why we are moved to do them, surely we should at least consider doing them! Particularly if no harm is likely to come from it. This is the voice of other parts of us, nudging us. Do we have any reason at all to resist opening the connection?
[November 27, 2005]
One Response to " When we are moved to do things … "
So, I wonder who or what you think it is that causes us to have these thoughts that seem to nudge us. Sometimes these thoughts are perfectly within our "comfort zone" and sometimes they are not. If on first reception we chose to ignore or debate the thought and it continues until we act then who or what are we obeying?


text:
We offer high-quality, competitively priced educational programs throughout the year. Whether face-to-face or online, our programs give you the chance to learn and network.
Whether you're selling a practice, looking for space, or pursuing new opportunities, look no further than our CDS dental classifieds, which receive more than 100,000 online views annually. Ads are also published in the CDS Review, the official magazine of the society.
Network with your colleagues and
other members of the dental community with the tools and resources in this
Nine convenient branches:
Informing members of the latest issues in dentistry is our mission. While we cover issues of national importance to the profession, we focus on news that affects our region and local communities.
Come to Chicago Feb. 23-25 for the 2017 Midwinter Meeting.
The CDS Foundation is dedicated to strengthening dental education and improving oral health care in our communities. We are a charitable 501(c)(3) tax-exempt organization.
Blue dates indicate one or more events
Join over 4,000CDS members.Stay connected!
Not a member?
Join now!
First-time visitor?
Register now!
Exmoor Country Club, 700 Vine Ave., Highland Park
North Suburban
Meridian Banquets, 1701 Algonquin Rd., Rolling Meadows
Northwest Suburban
CDS has learned that the Drug Enforcement Administration is auditing dentists to make sure their licenses to prescribe controlled substances are current. Without the proper licenses--or with an expired one--a dentist could be on the hook for thousands of dollars in fines.
Illinois dentists who prescribe controlled substances are required to register for a license through the state's Department of Financial and Professional Regulation (IDFPR). Dentists must also have a license from the Drug Enforcement Administration (DEA). In order to apply for the DEA license, you must have an Illinois license to prescribe controlled substances first.
To find out more about prescribing controlled substances in Illinois, see the ISDS web page, "Prescription Writing Authority."
To make sure you are compliant, follow these steps:
First, make sure that you are in good standing with IDFPR by keeping your Illinois license to prescribe controlled substances current. You can check your license status online.
If your license is expired, IDFPR advises that you come to their office in Springfield in person so you can get a "letter in good standing" that day. Otherwise, processing time is 4-6 weeks.
If you have never had a license to prescribe controlled substances in Illinois before, you should fill out the application and mail it in. Coming in person to Springfield does nothing except save mailing time. IDFPR will not process a first-time application in person. Processing time is currently 4-6 weeks.
If your license is current, be advised that the renewal period for dentists in not yet open. The license to prescribe controlled substances will expire on September 30 for dentists.
If you've applied before, you can renew online.
If you've never obtained a license from the DEA before, you can apply online.
Illinois Department of Financial and Professional Regulation
Springfield Office
320 West Washington Street
Springfield, Illinois 62786
Phone: (217) 785-0820
Drug Enforcement Administration
Diversion Control Program
230 S. Dearborn St.
Chicago, IL 60604
Phone: (312) 353-7875
dental news
state of illinois
A tradition of working for the dental profession. The Chicago Dental Society was organized in 1864 and incorporated in 1878. The objective of the Chicago Dental Society is to encourage the improvement of the health of the public, to promote the art and science of dentistry and to represent the intrest of the members of the profession and the public that it serves.
401 North Michigan AvenueSuite 200Chicago, Illinois 60611


text:
Best and worst winters: Astros (No. 28)
There are a lot of ways to lose games, but the most frustrating has to be having a bad bullpen. If you hate your bullpen, you can never enjoy a lead, knowing that once the manager starts playing Reliever Roulette it's only a matter of time until somebody's brains get splattered all over the scoreboard. Tis far worse to have led and lost than never to have led at all.
So the Astros might have looked at their 2009 season and drawn the conclusion that their bullpen -- 12th best in the National League, and 14th best in the seventh and eighth innings -- needed to be improved on. Their two best relievers were free agents, so the need was even great. Enter: Brandon Lyon and Matt Lindstrom. Lyon, with the 4.20 career ERA, who inexplicably got three years and $15 million from the Astros. Lindstrom, whose walk rate keeps going up, his bloated ERA dragging behind. I wouldn't kick either one out of my bullpen, but I wouldn't go out of my way to acquire them, either.
Look, there's nothing wrong with going cheap on your closer -- I don't necessarily think that Jose Valverde at two years and $14 million would have been a good deal. But they didn't go cheap, either. They just went bad.
The result: They don't have a shortstop. Or, rather, they'll rely on Tommy Manzella, a 27-year-old with a .695 career minor league OPS and five big league at bats.
Other moves: Signing Pedro Feliz to play third base for $4.5 million, and signing Brett Myers for $5 million. To their credit, Feliz it's been two years since Pedro Feliz has posted a sub-.300 OBP, and it's been more than three years since Myers punched his wife in the face. But the two moves -- and the Lyon signing -- point to a front office that can't make up its mind. Are they in contention? Then sign some good players, before Berkman, Oswalt and Lee really hit old their declines. Are they too far out of it to invest in 2010? Great, now shed some salary, rebuild a broken farm system, and quit signing mediocre players for $5 million to get, perhaps, a win or two closer to fourth place.
Most Popular
- Veterans David Booth, David Jones and Sean Bergenheim have no job guarantees
- The cause of skin irritations at Lake Forest school still a mystery
- Another encouraging outing for Alex Meyer as Angels top A's, 'clinch' fourth in AL West
- 3 Orange County schools win Blue Ribbon awards
- 2,300 sign counter-petition to reopen Knott's VR Halloween attraction
User Agreement
Comments are encouraged, but you must follow our Privacy Policy Policy & Terms of Use
Keep it civil and stay on topic. No profanity, vulgarity, racial slurs or personal attacks. People who harass others or joke about tragedies will be blocked. By posting your comment, you agree to allow Orange County Register Communications, Inc. the right to republish your name and comment in additional Register publications without any notification or payment.


text:
We are no longer offering Body Brush by Clarisonic. Discover a new favorite or contact our beauty concierge for further assistance.
The body brush leaves your whole body soft and glowing. The body brush exfoliates your skin, allowing lotions to absorb deeper. The body brush is a great prep for self tanners to give your skin beautiful, even coverage.
For cleansing areas of the body needing extra care and attention, including the décolleté, hands, arms, elbows and feet.
• Works with Clarisonic PLUS and PRO models.
• Brush heads should be replaced every 3 months
We cannot guarantee the efficacy, durability, or long term impact on the device itself, of brush heads not engineered by Clarisonic.
Where does b-glowing ship?
b-glowing ships anywhere in the world! Please view our international shipping policy for orders shipped outside the U.S
APO/FBO Addresses: b-glowing proudly ships to our military.
What shipping methods are offered by b-glowing?
Standard Shipping: $5.95 (COMPLIMENTARY standard shipping on orders $75+) within the contiguous U.S. (2-7 business days), Hawaii and Alaska (12-18 business days)
2-3 Business Day Shipping (for orders placed before 12pm Central time): + $11.00
1-2 Business Day Shipping (for orders placed before 12pm Central time): + $20.00
Any package containing hazardous material, such as nail polish, hair spray, or perfume, is restricted by the U.S. Department of Transportation to ground-only shipping methods.
When will my order ship?
Most orders are shipped 24-48 hours within receipt of order. We ship Monday through Friday. Orders placed on Saturday and Sunday will be shipped the following Monday or Tuesday. We do not ship on major holidays; orders placed on major holidays will be shipped the next business day. Please note that due to the speed of our ordering system, order cancellations and changes are not always possible.
All orders shipped complete, when all merchandise is in-stock; no partial orders shipped. You will not be charged until your order is shipped.
How can I track my order?
You can confirm delivery of a package at www.usps.com using the tracking number emailed to you at the time of shipping. UPS provides tracking for your orders at www.ups.com. Packages shipped via FedEx can be tracked at fedex.com. Please allow 24 hours after your order ships for your tracking updates to be made available.
We are not responsible for orders damaged or missing in transit via a mail forwarder. Please call (866)525-4933 for further assistance.


text:
Known as the godfather of the first British folk revival, Ewan MacColl is hailed for writing such classic songs as "The First Time Ever I Saw Your Face," "Dirty Old Town," "The Shoals of Herring" and "The Joy of Living." JOY OF ... more
Compass Records [email protected] 916 19th Avenue South, Nashville, TN, 37212 USA 800-757-2277
© 2003-2016 Compass Records. All Rights Reserved. Web Design by iDesign


text:
Serta Ivory Nights Plush Queen Mattress
1 year parts and labor
Ivory Nights Plush Queen Mattress Soothes You to Sleep Let Serta Ivory Nights plush queen mattress soothe you to sleep every night. With the word "plush" in its name, you know comfort is a key element. Every Serta Perfect Sleeper SmartSurface™ elite mattress comes equipped with sleep-promoting features: pressure-relieving comfort , proper back support, roll-off or sag prevention and balanced sleeping temperature. This mattress is designed to give both you and your partner undisturbed sleep. The Ivory Nights plush queen mattress features an innovative Smart Surface™ with MicroSupport® Gel Cool Balance® fabric technology to soothe your pressure points, cradle you in comfort as well as give you proper back support so you don't wake up with aches and pains, but with a smile. Also, Cool Twist™ gel memory foam, a liquid gel-enhanced memory foam, actually moves heat away from your body while you sleep, keeping you comfortable no matter how your body or the room temperature fluctuates. It's the stuff dreams are made of.
- Serta Ivory Nights plush queen mattress soothes you to sleep every night
- Smart Surface™ with MicroSupport® Gel Cool Balance® fabric technology relieves pressure points while providing proper back support
- Cool Twist™ gel memory foam helps move heat away from your body for a balanced, comfortable sleeping temperature
- 814 Free Flex® innerspring with Custom Support® combines continuous coil technology with TrueSense® coil designed for back support and undisturbed sleep-with up to 25% more support in the center of the innerspring
- TrueSense® motion isolating coils respond individually to body pressure and adjust to support you and your partner
- Comfort Last® construction with Total Edge® foam encasement helps prevent roll-off or sag regardless of body type, size or sleeping position
- 20-year limited warranty
Specifications & Dimensions
Product Documentation
More Like This
View Product
View Product


text:
The Bend Park & Recreation District Board of Directors is currently seeking candidates to fill a vacant board position until June 30.
It is anticipated the board will appoint the new board member at their Tuesday, February 19 meeting. The vacancy was created by Dallas Brown's resignation in January.
The board is composed of five members who serve four-year terms. Each member represents the district at-large rather than separate zones. This is a volunteer position and does not receive compensation.
To be considered for the board position, a candidate must:
-- Reside within the district boundaries.
-- Be a registered voter.
-- Be able to attend regularly scheduled and other periodic meetings.
-- Be willing to run for the seat in the May 2013 election for the term ending June 30, 2015.
To apply, candidates are to submit a letter of interest to: Chairman Scott Asla, Bend Park & Recreation District, 799 SW Columbia, Bend, OR 97702 or email firstname.lastname@example.com.
The application deadline is Friday, February 15. Applicants who meet position requirements will answer questions from the board and make a 3 - 5 minute presentation at the Tuesday, February 19, 4:00 pm board meeting. The new board member will be seated immediately following appointment to the position.
For additional information, contact Paula Lowery at (541) 706-6110 or email@example.com.


text:
My friend Kim has never had children, but she's had a great influence on the next generation. As a youth worker, speaker, writer, friend and aunt, she's faithfully shared the praiseworthy deeds of the Lord.
"We will tell the next generation the praiseworthy deeds of the Lord…so the next generation would know them…and they in turn would tell their children." Psalm 78:4-6
copyright Gail Burton Purath, 2011
You can join Gail several ways:
♥ On Bible Love Notes facebook page where she shares inspirational quotes and images as well as links to devotions.
♥ On Bible Love Notes Pinterest Page where you can pin devotions and spread God's Word.
♥ Or you can subscribe to Bible Love Notes below and have BLN sent to your email box each weekday. Be sure to validate the Feedburner email sent to your inbox.


text:
Craftsman 3000 PSI 2.7 GPM Gas-Powered Pressure Washer
$284.93 - $398.93
Store pickup
1 year parts and labor
Save Your Energy and Clean Up with the Craftsman 3000 psi Gas Pressure Washer The power of the 3000 psi Gas Pressure Washer with Grip & Go gives you precise water flow so you can wash away dirt, grime and debris from your porches, decks, patios and walkways. You don't have to prime or use a choke to get your engine to start with the Briggs & Stratton Ready Start system. Heavy-duty with up to 3,000 psi of water pressure, this durable 62 lb. power washer is no lightweight when it comes to cleaning up even ground-in grime or thick piles of leaves or yard debris. Whether you want a gentle spray or a powerful blast of water, the 5-in-1 selector nozzle lets you choose the right spray intensity for the job you're doing.
- This 3000 psi Gas Pressure Washer with Grip & Go does a professional job and has a GPM of 2.7
- The PerfectMix feature mixes the soap and water for you, so all you have to do is focus the water spray where you want it
- Plug in the battery to the DC charger, and you'll keep it ready for your next cleaning job
- The convenient 5-in-1 nozzle gives you the option to select the intensity of your water flow
- This product is compliant with California's CARB certification standards
Specifications & Dimensions
Product Documentation
More Like This
View Product
View Product
View Product
View Product


text:
Our Purpose
The World Clown Association exists to serve the needs of the members of the Association, to serve the needs of local affiliate clown alleys, and to promote the art of clowning throughout the world.
What Can World Clown Association Do for You?
- New Member informative packet with complimentary WCA patch
- Visa, MasterCard and PayPal accepted
- Life Memberships available
- WCA offers a variety of WCA merchandise
- WCA members that reside outside the continental United States pay a WCA convention registration fee in American dollars.
- The WCA Business Mgr is available at (800) 336-7922
- Clowning Around magazine is educational, informative, and published to provide you with useful clowning information.
- Start a WCA Alley with only 5 WCA members
- WCA offers a convention each year with education, competition and fellowship
- WCA makes available liability insurance at a very reasonable cost
- Awesome Jr. Joey program and instructors! Best manual for Jr. Joeys, Make-up training video starring Jr. Joeys, a Jr. Joey scholarship program and a How to start a Jr. Joey Alley manual
- BO DINO Scholarship program entitles the recipients the chance to further their clowning education at WCA approved educational opportunities (You must be a member of WCA for 2 years before applying.)
- Convention Committee that plans, organizes, and executes the most educational and entertaining annual conventions
- Active member of C.A.V.E. (Clowns Aiding Veterans Everywhere)
- Board of Directors that strives to give back to the clowning community


text:
For Women Who Want The Ballerific Life!
Like we previously reported in a Baller Mail post, Jason Campbell called off his wedding. In a text he tells friends that it was a "mutual" agreement to postpone the marriage and that he didn't leave his future wife at the alter.
He responds to a Washington Post article:
The wedding web site was elaborate and full of pictures of the happy couple. The bride-to-be excitedly tweeted every detail as she counted down the days to the big day. There were 23 attendants — not including the bride and groom — in the wedding party.
But former Redskins quarterback Jason Campbell and fiancée Yenicia " Jenny" Montes called off Saturday's ceremony just hours before the couple was scheduled to tie the knot. The 162 guests — who flew to an exclusive Dominican Republic resort for the celebration — were informed at a welcoming party that the marriage was off, but did not receive any explanation why.
In phone conversations with the Washington Post Tuesday, Campbell declined to go into details but said the two came to a decision to "put things off" after discussing it for a couple of weeks. "I love her enough not to leave her at the altar," he said. "I love her enough to talk to her before it gets that far."
Campbell, who said he was still in the Dominican Republic with Montes and her family, denied Internet rumors that he had called off the wedding at the last minute.
"That stuff is just crazy," he said. "Jenny's a good person and I'm a good person. I don't even know why people would put all those lies out there. " He said the two decided to go ahead with the trip to the Caribbean Island and "just made a vacation out of it." Except, of course, all their guests flew down expecting a wedding.
It was, to put it mildly, a surprising turn of events. Campbell, 30, and Montes, 32, have known each other for seven years and said their relationship was rooted in their deep friendship.
The two met when he first arrived in Washington in 2005 — he spotted the nightclub hostess dancing on a bar on her 25th birthday — and briefly dated.
"She was very independent," Campbell told our colleague Ellen McCarthy two weeks ago for an "On Love" profile that was scheduled to run after their wedding. "She didn't need anyone else to help her. I think guys appreciate that — someone who's out there trying to take care of themselves, rather than trying to lean on somebody." (Montes has always dreamed of owning a hair salon: "I'm not a stay at home mom.")
Montes, for her part, was taken by Campbell's manner. "He was such a gentleman," Montes said at the time. "I could tell he was brought up by great parents."
The initial romance didn't last, but their friendship did. "We wouldn't call each other every day, but when we talked we would talk for a long time," she told McCarthy. "When he had issues, problems, anything going on — relationship-wise, family-wise, or even if he had a bad day at work or during a game, he would call. He didn't hide anything from me. I didn't hide anything from him, because we were just friends."
Two years ago, after Campbell had broken up with a girlfriend and was headed to play for the Oakland Raiders, their romance reignited and they started dating again. He proposed on New Year's Eve of 2010 — his birthday — and the two moved in together in D.C., along with Montes's 8-year-old daughter from a previous relationship.
Montes had been regularly tweeting about "Papi," as she called her fiancé, their wedding and their house hunt in Atlanta. ("It Just hit me 2day that My signature is going 2 b Campbell n not Montes anymore,I need to start practicing my new campbell signature ASAP!")
But her groom-to-be was dealing with career issues: On the verge of becoming a free agent with the likelihood of lucrative new contract, Campbell broke his collarbone in a Raiders game against the Cleveland Browns in October. He was sidelined for the rest of the season, his pro football future suddenly thrown into question.
A subdued Campbell told McCarthy two weeks ago he was stressed and exhausted by the elaborate wedding planning, but that doesn't appear to be a big factor in the decision to call it off. "It's just the fact that I have a lot going on right now with recovering from injury," he said Tuesday. "There's just so much going on in both our lives right now."
The wedding web site was taken down Tuesday morning, and it's unclear if the marriage has been postponed or called off for good. "We're not trying to force anything right now," Campbell said. "We're taking everything one day at all time, trying to let all the air and the dust clear."
Well of course you didn't leave her at the ALTER Jason, because we reported that you dumped her a day before the wedding. And mutual? We don't believe you. Let's ask your "wife".
Baller Alert gets it right again.
Just received this Baller Mail,
Boss please don't feel sorry for this chic I was on lipstickalley and saw bragging ugly facebook statuses from this girl. Check this sh*t out
Jenny Montes
I'm thinking about doing a football wife/girlfriend show, just like basketball wife's but the difference would be that we are still with our man or still married
Jenny Montes
Jason can't make it, he already told your brother!!! Im humble all the way baby, I stay out of the spot light cuz that just isn't me!!! Lol but when I see the groupies tryin get involved!! I im in the spot light !! All the way!! Lol
Jenny Montes
So yesterday was my last night working at the club!My soon to be hubby pulled the plug, I will miss my co-workers friends n customer. I'm officially a stay home mom n wife!! Lol
******************** ************
Jenny Montes It is big brother!! I've been working in the club sene for 13 years!!! So "it's so hard to say goodby to yesterday" boyz IIMen!!! Lol but I'm starting a new chapter in my life so I will be just fine
******************** ************
Jenny Montes
Can ppl pls stop asking can they get an invite to our wedding!!! If you arent invite!! That's because we don't want you there!!! Hint!!! SMH
So yeah don't feel sorry for her at all. She was cocky and nasty!!!!!
Views: 7764
Ok but why though????Im dying to know.
Just updated it...
I see he trying to soften the blow... they decided to go anyway but their guests didn't know it wasn't going to be a wedding until they got there??? smh
Jason is still messy! At the end, he plays that 'It's not her, it's me stuff!'
She deleted her twitter https://twitter.com/dominicanmami00
Wow! Thanks for the update! First, Jenny doesn't want to be a stay at home mom. Now on lipstickalley she's reveling in it! Though Jason is messy for lying to all of his guests, karma is a b****!
She's a basic b**** & so is he...I don't understand how you are with someone for 7 years and then the times get rough and all of a suddent "we can't get married b/c we got a lot going on in BOTH OUR lives" well when u date that long. get engaged and are about to get married, it is not longer "both our lives". You guys stick it out. Well I guess it's better they called it off then do a divorce. So she was a damn cocktail waitress for 13 years? Wowzers
Wow...She deleted her twitter but it was mutual....I guess. Good thing I read her twitter before she deleted (I'm nosy). She was definitely a bragger to the point it was annoying and like she's never had nothing.
@Babydoll Well, since I live in DC, I guess I'll see Jenny at Love Nightclub this Saturday. It is sad that being a cocktail waitress and table dancing are the only skills she has in her early 30s.
@Brown I read her Twitter and realized it was true once she stopped posting. Jenny blabbered too much!
loose lips sink ships.... one of her friends shoulda told her.


text:
The Digital Skeptic: Airbnb Pumped Full of Investor Hot Air
"It gave everyone that level of trust," he said.
But now that Facebook manages a billion users, it is no surprise security remains one of its biggest challenge.
What I found so refreshing about talking with Bauer was his complete transparency on how the minutiae of growing a next-gen, trust-based service tends to be lost on investors. What happens, he said, is that people hear about Airbnb as if it were new, not realizing the company has worked for years to get where it is. And the trajectory of that company is not some easy direct flight into tomorrow. It is a long, complex, multi-stage flight with many stops, gusts and bumps.
"People have to understand that there is a story behind the story," he says. And the rush to participate can warp the value of what a business is trying to do.
Little room in first class
The biggest indicator of the difficult ride ahead for Airbnb is how crowded and bare-knuckled online travel has become. The days of sauntering into a market of slow-to-react, entrenched travel and lodging providers is long over. Big names such as Hilton, Sheraton, Southwest (LUV) and Delta (DAL) must push aggressively to keep interlopers such as Priceline (PCLN) , Kayak (KYAK) , Expedia (EXPE) and TripAdvisor (TRIP) out of the market.
These former disruptors are now a backbone of their own established -- and highly profitable -- virtual travel industry. Priceline CEO Jeffery Boyd said gross bookings were up about 25%, to about $7.8 billion, in the last quarter. And the company is pursuing mobile apps options to compete in the global market where Airbnb hopes to fly.
Bauer says that as new and creative as his and Airbnb's concepts might be, the major challenge he works on every day is making sure people will see value in RidePost.
"We have to give people incentives to continue to use the service," he says. "It's our challenge to create a product people want to use."
To these tired eyes, that means one thing: Airbnb's flight plan is to be yet another in a long line of oversold, good-only-for-insiders digital investments. Will it continue to grow? Sure. Will it be the next Priceline? Maybe. But this business is being built on a fundamentally new way to do business.
That means it's a long, bumpy flight ahead for Airbnb.


text: My SO has to stick to 2 cups or she feels really crappy, I can cane it all day long and still sleep nights, though I have never had more than about 5-6 mugs in a day. Creamy coffee tends to reduce the amount of meals I eat, so that;s probably not nutrionally optimal. But one coffee with cream a day is fine IMHO.


text:
Deep freeze impacting water pipes
MADISON, Wis. (AP) _ Frigid temperatures in Wisconsin are keeping plumbers busy.
They're dealing with frozen pipes that burst in residential properties. Officials say every homeowner should know where their water main shut off valve is located. That is the first course of action if a pipe freezes. Wrapping pipes with heating tape or coil is also recommended.
The City of Madison also has issues with its water system. Crews have been working around the clock to repair at least a dozen water main breaks throughout the city this week. Madison water utility spokeswoman Amy Barrilleaux says there wasn't enough insulating snow on the ground before temperatures plunged.


text:
Banquet in Salem to feature lasagna
SALEM - The Banquet in Salem will be served from 5 to 7 p.m. Monday at the Memorial Building, 785 E. State St. Sponsoring the meal is the First United Methodist Church of Salem. The menu offers lasagna, green beans, salad, fresh vegetables and fruit, cupcakes or watermelon.
Additional sponsors are needed. For more information call Patty Colian at 330-831-2169.
Breakfast buffet offered at Salem Masons
SALEM- Pancakes, waffles and bacon and eggs will be served at a breakfast buffet from 7:30 to 10 a.m. Saturday at the Masonic Building, 788 E. State St. Cost is $6 for adults, $3 for children under 10 and free for children under 2. Other items on the buffet table include sausage, homemade sausage gravy, biscuits, homefries, toast, fruit cocktail and beverages. The building is equipped with a handicap accessible elevator. Proceeds will be directed to the Salem Masonic Building Fund.
Pet show planned at Sterling House
SALEM - Sterling House will host its third annual pet show at 10:30 a.m. Aug. 1 in the outdoor courtyard. Pets will judged on best bark, best tail wag, best dressed and a variety of non-competitive fun categories. The pet show is free and open to the public. Refreshments will be served. For more information call 330-337-9096.
Audition dates set for "Unnecessary Farce"
SALEM - Audition dates for the comedy "Unnecessary Farce" by Paul Slade Smith are slated from 5:30 to 7:30 p.m. Aug. 3 and 6 to 8 p.m. Aug. 4 at the Salem Community Theatre, 490 E. State St.
This high-paced farce requires a cast of six actors, four men, roughly ages 20 to 50, and three women approximately ages 20 to 40. SCT's production is being directed by Youngstown's David El-Hatten. The show takes place in a cheap motel room, where an embezzling mayor is supposed to meet with his female accountant, while in the room next door, two undercover cops wait to catch the meeting on videotape.
But there's some confusion as to who's in which room, who's being videotaped, who's taken the money, who's hired a hit man, and why the accountant keeps taking off her clothes.
Rehearsals commence the first week of August, and show dates are weekends Sept. 12-21. Those auditioning should come prepared to read from the script and interact with other actors. For more information contact 330-332-9688 or salemcommunitytheatre.org.
Next swim lesson program begins Oct. 4
SALEM - The Salem Community Center will host another session of the American Red Cross swim lesson program Oct. 4 and running every Saturday to Nov. 22. Six learn to swim levels are available, along with a Mommy and Me level for infants and their parent. Cost is $70 for non-members and $55 for members. To sign-up call 330-332-5885.


text:
Caswell Springs United Methodist Church presents "A Salute to the Military" on Friday from 5 p.m. until. The dinner and talent show will benefit His Way Ministries, music and creative arts and youth ministry. Invite active duty service persons and veterans. Dinner is scheduled from 5-7 p.m. with the talent show to begin at 7:30 p.m.
The entertainment lineup will feature a variety of talents from the community, including piano duets, guitar playing, soloists, ensemble singing and karaoke. Dinner is $10 per plate. A love offering will be accepted at the talent show. Votes for best talent will be sold at the event.
To participate in the talent show contact Daniel Banke at 228-588-6546 or email at email@example.com; Ellie Wierson at 228-588-3162 or email at firstname.lastname@example.com or Rhonda Parker at 228-218-9202 or email at firstname.lastname@example.com.
Lunch orders are available for delivery and pickup. Large orders can be delivered by 11 a.m. the day of the event. To place a lunch order contact Joyce O'Brien at 228-627-1826 or email email@example.com.
The Caswell Springs Ministry Center is located at 18601 Hwy. 63, Moss Point.
Ambassadors Of Hope Ministry hosts 'One Night with the King' on Friday at 7 p.m. Guest speaker is Pastor Wilbert Odom of Omega Ministry. Worship in dance is minister Shevalle McCreary and psalmist is minister Tnffy Banks. The church is located at 1017 De La Pointe, Gautier.
The Shepherds House Ministries will host a singing on Saturday with Rod and Staff at 6 p.m. at the East Central Community Center. Admission will be free. There will be a love offering received. The pastors are "Steve" and Darlene Hicks and "Mickey" and Rhonda Powell. For more information contact Darlene at 228-249-4633 or 228-285-1637.
The East Central Community Center is located at 4300 Highway 614 in Hurley.
Christian Love Church is asking area churches to a musical leading up to the church anniversary. Choirs, male chorus', praise teams, soloists, and dance teams to render a selection. The event is Saturday at 6 p.m. The church is located at 4412 Chillis St., Moss Point. Rev. Graham is the presiding pastor.
St. Peter Baptist Church celebrates with family and friends day on Sunday at 3 p.m. The guest speaker will be Rev. Winfred Harper of Mount Calvary Missionary Baptist Church in Gulfport. For more information call 228-769-6927. Rev. William H. Marshall is the pastor. The church is located at 1320 South Market St., Pascagoula.
Little Rock Missionary Baptist Church will celebrate 95-year church anniversary on Sunday at 3 p.m. Guest speaker is Rev. Michael Davis, Pastor of Solomon Temple A.M.E. Zion Church and church family of Moss Point. The church is located at 4912 Gautier St., Moss Point and Rev. Cortez Keeton II is pastor.
St. Peter the Apostle Catholic Church will host a "Back to School Extravaganza" on Monday from 6-8 p.m. in the Education Building at 1715 Telephone Road, Pascagoula. Enjoy an evening of fun activities and be enlightened about getting back to school. This event is open to all kindergarten through 12th grade. For more information call 228-762-1759.
Morning Star Missionary Baptist Church has scheduled revival to be held Monday through Thursday. The service begins 7 p.m. nightly. The theme is "Made New in Christ." Guest Evangelist is Rev. Robert E. Manuel, pastor of Friendship Primitive Baptist Church of Prichard, Ala. Choirs are asked to render selections on this program.
Rev. Harvey M. Goudeau is the pastor. The church is located at 4943 Glaude St., Moss Point.
Parkway Baptist Church is featuring "Girl Talk", a club for girls in grades K-5 through sixth grade on Tuesday mornings from 9-11:30 a m. Activities include music, Bible study, prayer, food, and fun. Leaders are Rachel Rinks, Amanda Brewer, and JoAnn Clardy. Martin Britt is the pastor. Parkway Baptist is located at the corner of Jefferson and Macphelah.
Escatawpa Baptist Church schedule revival for Aug. 8 through 10. Services for Friday and Saturday are 11:30 a.m. luncheon and 7 p.m. Sunday services are 10:50 a.m. and 6 p.m. Guest speaker is pastor Don Dunavant of Clarksdale Baptist Church. Steve and Becky Carver are the Music Evangelists. Todd Bowen is the pastor presiding. For more information on revival call 228-475-2938.
The church is located at 7101Highway 613 Moss Point.
Christus Victor Lutheran Church will host a garage sale by the women of the Evangelical Lutheran Church in America (ELCA) on Saturday, Aug 9 from 8 a.m. to 1 p.m. in the blue room at the church. For more information call 228-875-2446. The church is located at 2755 Bienville Blvd., Ocean Springs.
Sister II Sister Women's Empowerment Network has scheduled a monthly women's community fellowship for Saturday, Aug. 9 from 11:30 a.m.-1:30 p.m. Enjoy a time of fun fellowship, inspirational teaching, and educational empowerment.
Sister II Sister is a community-based women's empowerment organization with a vision and mission to strengthen and unify women from diverse walks of life as we each aspire to wholeheartedly live, love, and lead through community, purity, power, and prayer. Questions or comments can be sent to email@example.com. To sponsor food items or door prizes for one or more of our monthly fellowships, send sponsorships to Sister II Sister Women's Network, P.O. Box 644, Pascagoula, Miss. 39567.
The event will be at the Pascagoula Library 3214 Pascagoula St., Pascagoula.
St. James United Methodist Church will host Family and Friends Day on Sunday, Aug. 10 at 3 p.m. Rev. Reginald Wells of Davis Chapel United Methodist Church is the guest speaker.
Rapheal D. Johnson is pastor presiding. The church is located at 30 Martin Luther King Road, Lucedale.
(To submit an item for the church events column, please e-mail it to firstname.lastname@example.com or fax it to 228-934-1474. The deadline is Tuesday at noon for publication on Fridays.)


text:
I bought a port replicator for my laptop. Since it lacks a serial,
parallel, and PS2 ports. And surprisingly, they are cheaper than a
serial to USB cable. This like most port replicators, hooks up through
one USB port. You also need drivers to make the port replicator operate
Anyway it was advertised as working with the Palm. And it does, except I
can't boot up, come out of Standby, or even Hibernation mode, with the
sync cable connected to the serial port on the port replicator. There is
a reset button (hold down for 5 seconds), but I never found it to be
helpful for anything yet. It just flashes the lights. lol
Anyway despite this slight problem, this thing is great. But is this
everyone else experience as well? What about those serial to USB cables?
This port replicator doesn't work with the serial UPS software. As the
UPS software can't see the port. But I can live without that. lol


text:
Lisa Caccavo ('03) running London Marathon
fundraising for leukemia and lymphoma society
2/9/04 - Lisa Caccavo ('03) will be running in her first marathon to raise awareness and financial support for the Leukemia and Lymphoma Society. She will be running the London Marathon on April 18. If you are interested in supporting Lisa in her effort, please contact her at email@example.com. or send a donation payable to Leukemia and Lymphoma Society to Lisa Caccavo, Sedgwick, Detert, Moran & Arnold, LLP, 125 Broad Street, 39th Floor, New York, NY 10004.


text:
From Proteopedia
Crystal Structure Analysis of the Microbial Transglutaminase
Structural highlights
[TGAS_STRMB] Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins.
Evolutionary Conservation
Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.
Publication Abstract from PubMed
The crystal structure of a microbial transglutaminase from Streptoverticillium mobaraense has been determined at 2.4 A resolution. The protein folds into a plate-like shape, and has one deep cleft at the edge of the molecule. Its overall structure is completely different from that of the factor XIII-like transglutaminase, which possesses a cysteine protease-like catalytic triad. The catalytic residue, Cys(64), exists at the bottom of the cleft. Asp(255) resides at the position nearest to Cys(64) and is also adjacent to His(274). Interestingly, Cys(64), Asp(255), and His(274) superimpose well on the catalytic triad "Cys-His-Asp" of the factor XIII-like transglutaminase, in this order. The secondary structure frameworks around these residues are also similar to each other. These results imply that both transglutaminases are related by convergent evolution; however, the microbial transglutaminase has developed a novel catalytic mechanism specialized for the cross-linking reaction. The structure accounts well for the catalytic mechanism, in which Asp(255) is considered to be enzymatically essential, as well as for the causes of the higher reaction rate, the broader substrate specificity, and the lower deamidation activity of this enzyme.
Crystal structure of microbial transglutaminase from Streptoverticillium mobaraense.,Kashiwagi T, Yokoyama K, Ishikawa K, Ono K, Ejima D, Matsui H, Suzuki E J Biol Chem. 2002 Nov 15;277(46):44252-60. Epub 2002 Sep 7. PMID:12221081[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


text:
IDB and Nicholas Stern Present Country Studies on Climate Impact
5 March 2009: Lord Nicholas Stern and the Inter-American Development Bank (IDB) hosted a seminar on "Development in a More Hostile Climate" during which country-level studies of the economic impact of climate change in Brazil, Mexico and South East Asia were presented.
The meeting included discussions on the opportunities for reducing long-term impacts through investing in clean energy, the threats to development posed by climate change, strategies for overcoming risks and the role of partnerships and multilateral institutions in responding to climate investment challenges faced by developing countries. The event was complementary to a symposium titled "US Climate Action: A Global Economic Perspective," organized by Lord Stern and the World Resources Institute. [IDB Press Release]


text:
"She's really relaxed and wants something comfortable and great," big sister Haylie Duff said Monday at the Tribeca Film Festival premiere of the documentary Earth Made of Glass. "She's just so excited to be engaged."
Comrie, 29, who plays for the Edmonton Oilers, proposed to Hilary, 22, over Christmas in Hawaii. Four months later, she and her sister are still in the early stages of planning the nuptials.
"We've started talking about the wedding stuff, but she's still just really happy in this sort of phase," says Haylie, 25. "It'll be a while, but it's fun to talk about it and think about it."
Luckily, Haylie hasn't to deal with any bridezilla-like antics from her little sister. "She's just not the [type]," she says. "One of my other best friends got married and was a complete bridezilla, so I'm not getting the signs from Hilary that that's the case."
Haylie was attending the Earth Made of Glass premiere to support her friends Channing Tatum and Jenna Dewan, who were producers on it. The film is a documentary about about the Rwandan genocide.
See what other readers have to say about this story – or leave a comment of your own


text:
Download citation file:
From the University of Otago, Christchurch, New Zealand; Cleveland Clinic, Cleveland, Ohio; University of Sydney and George Institute for International Health, Sydney, and University of Queensland at Princess Alexandra Hospital, Brisbane, Australia; University of Alberta, Edmonton, and University of Calgary, Calgary, Alberta, Canada; University of Western Ontario, London, Ontario, Canada; Mario Negri Sud Consortium, Santa Maria Imbaro, Italy; Scientific Institute Casa Sollievo della Sofferenza, Foggia, Italy; and Diaverum, Lund, Sweden.
Acknowledgment: The authors acknowledge the help of Ruth Mitchell, Trial Search Coordinator, and Narelle Willis, Managing Director, from the Cochrane Renal Group.
Potential Conflicts of Interest: Dr. Johnson: Consultancies: Amgen, Roche, Janssen-Cilag, Sandoz; Grants/grants pending, honoraria, and travel/accommodations expenses covered or reimbursed: Amgen, Roche, Janssen-Cilag; Payment for development of educational presentations including service on speakers' bureaus: Amgen, Janssen-Cilag. Dr. Tonelli: Grants/grants pending (money to institution): Amgen. Dr. Garg: Other: Ortho Biotech funds a research scholarship (unrestricted educational grant) at the University of Western Ontario that provides partial salary support to physicians pursuing additional years of research training; Dr. Tonelli has supervised some of these research projects. Dr. Jardine: Grants received (money to institution): Royal Australasian College of Physicians Servier Staff Postdoctoral Fellowship. Dr. Perkovic: Grants/grants pending (money to institution): Australian National Health and Medical Research Council Project Grants, Baxter, Johnson & Johnson, Novartis, Roche, Servier, Amgen; Honoraria: Abbott, AstraZeneca, Roche, Servier. Dr. Strippoli: Grants/grants pending (money to institution): Italian Agency for Drugs (independent research funding body for CEDOSE [Clinical Evaluation of the Dose of Erythropoietins], independently funded by Agenzia Italiana del Farmaco). Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-0120.
Reproducible Research Statement:Study protocol, statistical code, and data set: Available from Dr. Strippoli (e-mail, firstname.lastname@example.com).
Requests for Single Reprints: Giovanni F.M. Strippoli, MD, PhD, MPH, MM, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud and Diaverum Medical Scientific Office, Via Nazionale 8/a, 66030 S. Maria Imbaro, Italy; e-mail, firstname.lastname@example.com.
Current Author Addresses: Dr. Palmer: Renal Division, Brigham and Women's Hospital, Harvard Institute of Medicine, Room 550, 4 Blackfan Circle, Boston, MA 02215.
Dr. Navaneethan: Cleveland Clinic Main Campus, Mail Code Q7, 9500 Euclid Avenue, Cleveland, OH 44195.
Drs. Craig and McGee: Centre for Kidney Research, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales 2145, Australia.
Dr. Johnson: Department of Renal Medicine, Level 2, Ambulatory Renal and Transplant Services Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia.
Dr. Tonelli: University of Alberta, Department of Medicine, Division of Nephrology and Immunology, Clinical Sciences Building 7-129, Edmonton, Alberta T6G 2G3, Canada.
Dr. Garg: Department of Medicine and Epidemiology, University of Western Ontario and Division of Nephrology, London Health Sciences Centre, Room ELL-101, Westminster Tower, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.
Mr. Pellegrini and Drs. Graziano, Nicolucci, Tognoni, and Strippoli: Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 S. Maria Imbaro (Chieti), Italy.
Dr. Ravani: Department of Community Health Sciences, Faculty of Medicine, University of Calgary, TRW Building, 3rd Floor, 3280 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada.
Drs. Jardine and Perkovic: The George Institute for International Health, PO Box M201 Missenden Road, Sydney, Camperdown, New South Wales 2070, Australia.
Author Contributions: Conception and design: S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, G.F.M. Strippoli.
Analysis and interpretation of the data: S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, M. Tonelli, A.X. Garg, F. Pellegrini, P. Ravani, M. Jardine, G. Graziano, R. McGee, A. Nicolucci, G.F.M. Strippoli.
Drafting of the article: S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, V. Perkovic, R. McGee, G.F.M. Strippoli.
Critical revision of the article for important intellectual content: S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, M. Tonelli, A.X. Garg, F. Pellegrini, P. Ravani, M. Jardine, V. Perkovic, A. Nicolucci, G. Tognoni, G.F.M. Strippoli.
Final approval of the article: S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, M. Tonelli, A.X. Garg, F. Pellegrini, P. Ravani, M. Jardine, V. Perkovic, R. McGee, A. Nicolucci, G. Tognoni, G.F.M. Strippoli.
Provision of study materials or patients: G.F.M. Strippoli.
Statistical expertise: J.C. Craig, D.W. Johnson, F. Pellegrini, G. Graziano, R. McGee, G.F.M. Strippoli.
Administrative, technical, or logistic support: G. Tognoni.
Collection and assembly of data: S.C. Palmer, S.D. Navaneethan, F. Pellegrini, G.F.M. Strippoli.
Background: Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed.
Purpose: To summarize the effects of ESA treatment on clinical outcomes in patients with anemia and CKD.
Data Sources: MEDLINE (January 1966 to November 2009), EMBASE (January 1980 to November 2009), and the Cochrane database (to March 2010) were searched without language restriction.
Study Selection: Two authors independently screened reports to identify randomized trials evaluating ESA treatment in people with CKD. Hemoglobin target trials or trials of ESA versus no treatment or placebo were included.
Data Extraction: Two authors independently extracted data on patient characteristics, study risks for bias, and the effects of ESA therapy.
Data Synthesis: 27 trials (10Â 452 patients) were identified. A higher hemoglobin target was associated with increased risks for stroke (relative risk [RR], 1.51 [95% CI, 1.03 to 2.21]), hypertension (RR, 1.67 [CI, 1.31 to 2.12]), and vascular access thrombosis (RR, 1.33 [CI, 1.16 to 1.53]) compared with a lower hemoglobin target. No statistically significant differences in the risks for mortality (RR, 1.09 [CI, 0.99 to 1.20]), serious cardiovascular events (RR, 1.15 [CI, 0.98 to 1.33]), or end-stage kidney disease (RR, 1.08 [CI, 0.97 to 1.20]) were observed, although point estimates favored a lower hemoglobin target. Treatment effects were consistent across subgroups, including all stages of CKD.
Limitations: The evidence for effects on quality of life was limited by selective reporting. Trials also reported insufficient information to allow analysis of the independent effects of ESA dose on clinical outcomes.
Conclusion: Targeting higher hemoglobin levels in CKD increases risks for stroke, hypertension, and vascular access thrombosis and probably increases risks for death, serious cardiovascular events, and end-stage renal disease. The mechanisms for harm remain unclear, and meta-analysis of individual-patient data and trials on fixed ESA doses are recommended to elucidate these mechanisms.
Primary Funding Source: None.
Recent studies suggest that treating anemia of chronic kidney disease can sometimes cause harm.
This review compiles 27 randomized trials of erythropoiesis-stimulating agents (ESAs) in patients with anemia and chronic kidney disease. Treatment with ESAs that resulted in higher hemoglobin levels increased risks for stroke, worsening hypertension, and vascular access thrombosis more than strategies that resulted in lower hemoglobin levels (placebo, no treatment, or lower ESA dose). Effects on all-cause mortality, cardiovascular events, and quality of life were unclear.
Underlying mechanisms for harms were not established.
Therapy with ESAs that targets high hemoglobin levels is harmful for patients with chronic kidney disease.
—The Editors
Anemia frequently complicates chronic kidney disease (CKD) (1), in part because of deficient renal erythropoietin release (2). Phase 1 and 2 clinical trials first evaluated recombinant human erythropoietin replacement therapy in 1986 and 1987 in patients receiving hemodialysis. These trials demonstrated dose-dependent increases in hemoglobin levels and avoidance of red blood cell transfusions (3–6), but they also reported incidence of hypertension and vascular thrombosis (3, 5–6). Subsequent randomized, placebo-controlled trials (7–16) concluded that erythropoietin treatment was associated with some improvement in quality of life at the expense of increased risk for hypertension and vascular thrombosis. From 1998 until 2009, all randomized trials compared 2 active erythropoiesis-stimulating agent (ESA) regimens to achieve higher and lower hemoglobin targets.
An earlier meta-analysis of 9 randomized trials involving 5143 patients with CKD concluded that targeting a higher hemoglobin concentration (typically 120 to 150 g/L) versus a lower concentration (95 to 115 g/L) was associated with an increased risk for all-cause mortality, arteriovenous access thrombosis, and hypertension (17). Since then, a large placebo-controlled trial of darbepoetin in patients with diabetes mellitus and CKD (TREAT [Trial to Reduce Cardiovascular Events with Aranesp Therapy]) has been completed (18).
In this present systematic review, we summarize the benefits and harms of treating anemia with an ESA and included data from all existing randomized trials. Using cumulative meta-analysis, we explore when the beneficial and harmful effects of ESA treatment and hemoglobin targets first became evident.
We followed a prespecified and peer-reviewed study protocol (19) and substantively updated a previous review and added multiple additional analyses, including a cumulative meta-analysis.
Two independent authors searched MEDLINE (January 1966 to November 2009) and EMBASE (1980 to November 2009) by using optimally sensitive search strategies developed by the Cochrane Collaboration. They also searched the Cochrane Renal Group trial register and the Cochrane Central Register of Controlled Trials for randomized, controlled trials to November 2009. The Cochrane search was updated to March 2010. Appendix Table 1 includes the full search strategies. Two authors identified eligible trials according to the inclusion criteria and without language restriction. They resolved any disagreements by discussion with an arbitrator.
We included randomized, controlled trials of at least 3 months' duration that allocated patients to ESA versus placebo, no treatment, or different ESA doses to achieve a higher hemoglobin target versus a lower hemoglobin target. Trials of erythropoietin-alfa or -beta, darbepoetin, or a continuous erythropoietin receptor activator at any dose and route of administration were eligible. We assumed that placebo-controlled trials were comparing 2 treatment targets for hemoglobin, although explicit targets were not always described. Trials of populations with any stage of CKD were included.
Two authors independently extracted data on characteristics of the participants, interventions, and clinical outcomes. Both reviewers also assessed the risks for bias in trials according to standard criteria (allocation concealment, blinding of patients, investigators and outcome assessors, completeness to follow-up, and use of intention-to-treat analysis) (20). The reviewers resolved any discrepancies in data extraction by discussion with an arbitrator.
We summarized treatment effects as relative risks (RRs) for dichotomous outcomes or mean differences for continuous outcomes with 95% CIs by using the DerSimonian and Laird random-effects model to pool data. We tested for heterogeneity of treatment effects between studies with the Cochran Q and the I2 statistics (21). In cumulative meta-analysis, outcomes were accrued according to the year of publication. Through subgroup analysis and univariate random-effects meta-regression analysis, we investigated the impact of the following plausible effect modifiers on outcomes: stage of CKD (stage 2 to 5 not requiring dialysis vs. stage 5 requiring dialysis); trial design (ESA vs. ESA or ESA vs. placebo or no treatment); baseline hemoglobin concentration; age; proportion of trial participants with diabetes mellitus, hypertension, or cardiovascular disease; baseline blood pressure; duration of administration of the intervention (<6 months, 6 to 12 months, 12 to 24 months, or >24 months); blinding of patients, investigators, or outcome assessors; intention-to-treat analysis; study attrition (≥10% or <10%); and number of trial participants (0 to 100, 101 to 500, or >500). Earlier studies tended to have very low event rates in 1 or both study groups. Our primary analyses used the standard continuity correction of 0.05 to estimate the RR for these trials. We also conducted a sensitivity analysis by using continuity corrections of 0.0001, 0.001, and 0.01 to evaluate the robustness of our results. We found no changes for the point estimates for treatment effects or their 95% CIs. All analyses were conducted with SAS, release 9.1 (SAS Institute, Cary, North Carolina).
No specific funding was received for any aspect of this study. All authors had full access to the study data and had final responsibility for the decision to submit the manuscript for publication.
We identified 27 randomized trials (10 452 participants) that met the inclusion criteria (Appendix Figure). All were randomized, controlled trials that enrolled patients with CKD for treatment with ESA. The study design changed over time from smaller placebo-controlled trials with relatively lower hemoglobin targets to larger active comparator trials with higher hemoglobin targets. This change occurred around 1998, after about a decade of randomized trial research. It was heralded by the publication of a large trial (1233 patients) by Besarab and colleagues (22) conducted in patients with end-stage kidney disease requiring hemodialysis for renal replacement therapy. Between 1989 and 1998, all 10 available trials enrolled fewer than 160 patients (median, 55 patients; interquartile range [IQR], 13 to 94 patients) (7–16). From 1998 onward, trials were larger (median number of participants, 172; IQR, 91 to 600), and 3 trials included more than 1000 patients (18, 22–23). Earlier studies were conducted both in patients requiring dialysis and in those with earlier stages of CKD. After 2003, all but 1 (24) of 11 studies were performed in patients with moderate to severe CKD (estimated glomerular filtration rate ranged from 15 to 79 mL/min per 1.73 m2).
CENTRAL = Cochrane Central Register of Controlled Trials; RRT = renal replacement therapy.
* Numbers do not sum to 1637 because some articles were identified by more than 1 search.
The treatment comparisons in the identified trials were either ESA (erythropoietin-alfa or -beta or darbepoetin) versus placebo or no treatment or different doses of ESA therapy as needed to achieve 2 (higher vs. lower) hemoglobin target levels. Doses of ESA used in the trials were not available in one third of the study reports (Appendix Table 2). Studies published before 1998 were all placebo-controlled (7–16), whereas trials published from 1998 until 2009 compared 2 different doses of ESA therapy (18, 22–37). The exception to this more recent trend of active comparator trials was the largest study to date, published in 2009, which was again placebo-controlled (18).
Trials completed before 1998 targeted a lower hemoglobin level in the high hemoglobin versus active ESA treatment groups than that of trials published later. With the exception of a trial of 14 patients with hemoglobin level targets between 126 and 133 g/L (10), the remaining smaller trials before 1998 had higher hemoglobin targets between 95 and 120 g/L (7–9, 12, 14). Trials from 1998 to 2008, all using ESA as the active comparator, had higher hemoglobin targets between 120 to 150 g/L versus lower targets between 90 to 120 g/L (22–37). In the more recent trials, the lower hemoglobin target range was similar to the higher range in older trials. In all trials, the median hemoglobin target achieved by treatment in the high hemoglobin groups was 130 g/L (IQR, 120 to 140 g/L) (10–11, 16, 22, 24–26, 28, 31–33, 36); the corresponding value in the low hemoglobin target groups was 101 g/L (IQR, 92 to 110 g/L) (11, 14, 16, 22, 24–26, 28, 31–33, 36).
Most studies enrolled participants between 50 and 60 years of age on average. In the 3 largest trials of more than 1000 patients each, patients were generally older than 60 years (18, 22–23). Two small studies were conducted in children (12, 26). We identified 3 trials (1413 patients) that included only patients with established cardiovascular disease (22, 25, 30) and 2 trials (4210 patients) that included only patients with diabetes mellitus and CKD (18, 35). Appendix Tables 2 and 3 summarize the characteristics of all trials included in our analysis.
By current methods standards, trial quality was suboptimal. In addition, many trials were not reported according to the CONSORT (Consolidated Standards of Reporting Trials) statement (Figure 1) (38–39). None of the 27 trials reported the details of allocation concealment (the method by which the person responsible for treatment allocation is made unaware of a participant's treatment assignment). Twelve of 16 trials published before 2004 did not conduct analysis by the intention-to-treat principle, whereas all but 1 of 11 trials from 2004 onward analyzed data according to randomized treatment allocation. Study attrition was higher in studies before 1998 (median, 15%; IQR, 2 to 32%) than in studies from 1998 onward (median, 2%; IQR, 0 to 9%). Larger trials that explored major patient-level outcomes (all-cause mortality or major adverse cardiovascular events) were generally of better methodological quality.
We assessed study risk for bias according to recommendations from the Cochrane Collaboration (20).
* Whether the study reported methods to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been predicted in advance of patient enrollment.
† Methods by which patients, investigators, or outcomes assessors are protected from being aware of the treatment allocations after patients are included in the study.
‡ Whether the study conducted the major analyses according to the patients' treatment assignment at the time of randomization.
§ Whether the study described the completeness of outcome data for the primary outcomes.
Risks for fatal and nonfatal stroke, vascular access thrombosis, and worsening hypertension were increased with a higher hemoglobin target than with a lower hemoglobin target (Figure 2). Important heterogeneity among trials for hypertension findings was explored through meta-regression. Patients randomly assigned to a higher hemoglobin target were less likely to require a blood transfusion (8 trials; 6482 patients) (RR, 0.61 [95% CI, 0.49 to 0.77]) (8, 10, 14, 18, 22, 26, 29, 37) but were more likely to receive intravenous iron therapy (6 trials; 2283 patients) (RR, 1.57 [CI, 1.13 to 2.20]) (7, 13, 22, 24, 31, 33). Heterogeneity in the analysis for iron treatment (heterogeneity chi-square = 21.38; P < 0.001) was possibly due to more frequent use of iron supplementation in older, placebo-controlled trials.
ACORD = Anemia Correction in Diabetes; EPO = erythropoietin; CHOIR = Correction of Hemoglobin and Outcomes in Renal Insufficiency; CREATE = Cardiovascular Risk Reduction in Early Anemia Treatment with Epoetin Beta; NHS = Normal Hematocrit Study; TREAT = Trial to Reduce Cardiovascular Events with Aranesp Therapy.
We found no statistically significant difference in the risk for all-cause mortality, serious cardiovascular events, or fatal and nonfatal myocardial infarction between a higher hemoglobin target and a lower target (Figure 2). In the 10 studies conducted in people with CKD who were not dialysis-dependent, the risk for end-stage kidney disease requiring renal replacement therapy did not statistically significantly differ when hemoglobin target groups were compared (Figure 2). We also found no statistically significant differences between treatment groups in left ventricular mass at the end of treatment (4 trials; 1544 patients; mean difference, 0.14 g/m2 [CI, −4.60 to 4.88 g/m2]) (24, 34–36).
We rated the evidence for treatment effects on quality of life to be of low quality, with high risks for bias due to selective reporting of outcomes. Appendix Table 4 summarizes the quality-of-life data reported in 15 trials. The Short Form-36 Health Survey (SF-36) was the most commonly used tool for assessment of quality of life, reported in 9 trials (18, 22–24, 29–30, 35–37). The SF-36 assesses 8 domains: limitation of physical activity, social function, physical role, bodily pain, mental health, emotional role, vitality, and general health perception. Of importance, only 2 trials reported treatment effects on quality of life for all 8 of the SF-36 outcome domains (23, 37) and only 1 trial (7) reported treatment effects on utility. The most recent, large, and well-designed trial reported no differences in mean change in scores between groups for energy or physical function quality-of-life domains.
We performed a cumulative meta-analysis to identify when evidence for the benefits and harms of ESA therapy first became evident. Collectively, small placebo-controlled trials conducted before 1998 showed effect estimates favoring a higher hemoglobin target for all-cause mortality, serious cardiovascular events, and nonfatal and fatal stroke (Figure 3), whereas larger, active comparator trials with higher hemoglobin targets conducted from 1998 onward favored a lower hemoglobin target and showed risk for harm when targeting higher values. Specifically, when the first trial to include more than 1000 patients was completed in 1998 (22), cumulative evidence for a probable increased risk for death with a higher hemoglobin target became apparent. Across the following decade, the accrual of 12 further trials with 8233 additional patients and 1063 events did not materially influence the point estimates or confidence intervals for excess mortality that were first identified in 1998.
A probable increased risk for serious cardiovascular events with a higher hemoglobin target was evident in 2006 after trials had randomly assigned 2670 patients (433 events), and this risk remained consistent across subsequent trials that enrolled 4210 patients with 1245 additional events. A probable increase in the risk for stroke with ESA treatment to a higher hemoglobin target was first indicated in 1998 and was confirmed by the placebo-controlled trial by Pfeffer and colleagues (18). Evidence for increased risks for worsening hypertension and vascular access thrombosis with a higher hemoglobin target was evident from trials conducted in 1990, with point estimates unchanged and increased precision for treatment effects available for these outcomes over time.
We conducted subgroup analyses and univariate meta-regression to explore trial-level factors (patients, intervention, and design) that may affect the risks for all-cause mortality, worsening hypertension, and stroke (fatal and nonfatal) (Appendix Table 5). When the 2 primary trial designs were compared (placebo-controlled vs. active ESA comparator), the treatment comparison did not influence the risk for all-cause mortality or stroke. The stage of kidney disease (dialysis vs. predialysis) was not an effect modifier for any of the examined outcomes, suggesting that the findings of this meta-analysis may be generalized to any stage of CKD. When we explored the reasons for heterogeneity in the risk for worsening hypertension, we found a lower risk with a higher hemoglobin target in longer trials, trials with more participants, and trials where adjudication of outcomes was not blinded. As the prescribed ESA dose and the hemoglobin level achieved were inconsistently reported across trials (as seen in Appendix Table 2), we could not further explore the possible role of these factors on the risk for any outcome.
We found that treatment with either erythropoietin or darbepoetin to higher target hemoglobin levels in patients with CKD (any stage) increased the risk for stroke, worsening hypertension, and vascular access thrombosis, compared with treatment to a lower hemoglobin target. We found no statistically significant differences between higher and lower hemoglobin targets for the risk for all-cause mortality, serious cardiovascular events, or end-stage kidney disease, but point estimates for all outcomes favored a lower hemoglobin target and effectively excluded the likelihood of any clinically relevant benefit for a higher hemoglobin target. Targeting a higher hemoglobin level was linked to a reduction in need for red blood cell transfusions but greater prescription of intravenous iron therapy. We identified no clinically important effects of ESA therapy on quality of life.
Cumulative meta-analysis demonstrated that evidence for harm associated with ESA therapy to achieve higher hemoglobin targets has remained stable since it became apparent in 1998. Before 1998, small placebo-controlled trials with relatively lower hemoglobin targets suggested that adverse clinical outcomes in CKD might be prevented with partial anemia correction compared with no treatment. In these earliest studies, ESA therapy alleviated the need for red blood cell transfusions, and therefore the need to test erythropoietin against placebo in a large trial was not advocated until more recently. A switch to larger trials in 1998 targeting higher hemoglobin values unexpectedly demonstrated that these higher hemoglobin targets were harmful. Addition of 12 further trials after 1998 did not alter the probable increased risks for mortality that was first identified by Besarab and colleagues (22), although the trials supporting this conclusion all compared 2 different doses of ESA therapy. A placebo-controlled trial of ESA therapy was conducted (TREAT [18]). Now completed, this large trial tested whether treatment with darbepoetin to achieve a hemoglobin target of about 130 g/L would "beat" placebo (rescue ESA therapy at a hemoglobin level <90 g/L) (40). It confirmed that, apart from preventing red blood cell transfusions, treating anemia with ESA therapy is not efficacious and is in fact harmful.
Consistent with these data, increased mortality associated with higher hemoglobin targets using ESA treatment has also been demonstrated in patients with anemia and cancer. A meta-analysis of individual-patient data of erythropoietin or darbepoetin versus placebo (53 trials; 13 933 patients) found that treatment with an ESA was associated with significantly worse overall survival than was no treatment (hazard ratio, 1.06 [CI, 1.00 to 1.12]) (41–42). Although a much smaller meta-analysis of placebo-controlled trials of ESA versus placebo (7 trials; 650 patients) in patients with anemia and heart failure did not find a relationship between ESA treatment and mortality (43), a large, event-driven study of darbepoetin versus placebo is currently under way in patients with New York Heart Association class II to IV heart failure and anemia (hemoglobin target, 90 to 120 g/L) (RED-HF [Reduction of Events with Darbepoetin alfa in Heart Failure] trial) (44). The consistency of our findings compared with those identified in other populations suggests that the design of any ongoing trial in this setting must be carefully assessed. Our findings are also consistent with those of a previous meta-analysis of 8 trials evaluating target hemoglobin levels in CKD that showed an increase in the risk for all-cause mortality with higher hemoglobin levels (RR for all-cause mortality, 1.17 [CI, 1.01 to 1.35]) (17). We provide a more precise estimate (that is, a narrower confidence interval) of mortality risk (18 trials) (RR, 1.09 [CI, 0.99 to 1.20]) with higher hemoglobin targets than that previously reported by including more trials and patients. Of note, the lack of statistical significance found in the present meta-analysis for mortality is probably due to the smaller point estimate that we found (9% vs. 17%), which is, however, consistent with that reported in the larger meta-analysis of trials in patients with cancer (42).
In the absence of a survival advantage for ESA therapy, improving quality of life has become the key rationale for treating anemia in CKD. We found that evidence for quality of life was suboptimal because of selective reporting, suggesting potential overestimation of the benefits of anemia correction. Data from large and well-conducted trials did not support clinical efficacy for ESA therapy on quality of life (18). We found that ESA therapy was associated with a reduction in the need for blood transfusions, although the clinical relevance of this observation needs to be considered in light of the harms demonstrated in randomized trials of ESA to date, increased rates of intravenous iron therapy associated with higher hemoglobin targets, expense of ESA administration, and relatively low risks for transfusion-associated infection in the modern era.
Targeting higher hemoglobin levels with ESA therapy worsens hypertension. Although greater risks for hypertension were evident in smaller studies of lower quality and with shorter follow-up, larger trials with lower risks for bias also demonstrated increased risks for worsening hypertension with a higher hemoglobin target. The hypertensive effects of ESA therapy in the higher hemoglobin target group of all trials to date suggest that ESA therapy might mediate excess vascular events through nonhematopoietic erythropoietin receptor activation in vascular tissues (45), although this hypothesis remains speculative.
Using subgroup and meta-regression analysis, we identified consistent treatment-related risks for death and stroke associated with higher hemoglobin levels across all trials. Risks were similar across all stages of CKD and were not dependent on trial method quality or intervention. We could not specifically address the important question of whether the increased risk for adverse outcomes with higher hemoglobin levels was due to the ESA dose required in the individual patient to achieve the targeted hemoglobin level rather than the hemoglobin target (46–48). Understanding the independent effect of ESA dose on outcomes in CKD now demands that treatment dose (and not hemoglobin target) is the randomized intervention in adequately powered trials and that dose and other data from existing trials should be made available for more refined analyses. Our findings indicate that, on the basis of the available trial evidence, the rationale for the recommended hemoglobin target of 110 to 120 g/L in the National Kidney Foundation clinical practice guideline on recommendations for anemia in CKD is unclear (49–50). We found no evidence that higher hemoglobin targets in CKD are associated with benefit and conclude that anemia treatment using ESA is associated with possible or absolute harm across all major clinical outcomes.
Our review has limitations. First, the evidence for ESA therapy to improve quality of life is based largely on selective reporting of outcomes and is generally of low quality. Second, the available trial data do not identify the mechanisms by which ESA therapy may be harmful. Third, trials reported insufficient information to allow analysis of the independent effects of ESA dose on outcomes. A meta-analysis of individual-patient data might allow preliminary exploration of the specific patient and intervention characteristics that predict harm with ESA therapy.
In conclusion, ESA therapy targeting higher hemoglobin levels leads to increased risks for vascular and fatal events compared with therapy targeting lower levels. Evidence for harm when targeting higher hemoglobin values in CKD has now been available for more than 20 years, and this evidence should be incorporated in guidelines and adopted in clinical practice. The case is strong for making the best use of the considerable amount of information on hemoglobin targets available in existing trials by conducting meta-analysis of individual-patient data. The nephrology community should focus strongly on exploring these existing data and designing, conducting, and achieving funding for fixed-dose ESA trials.
Please read the other comments before posting. Contributors must reveal any conflict
of interest.
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
Anyone can submit a comment any time after publication, but only those submitted within 4 weeks of an article's publication will be considered for print publication. One month after publication, editors review all posted comments and select some for publication in the Letters section of the print version of Annals. (Not peer reviewed)
Authors: No more than 5
Text: Word Limit 400 (excludes references), 5 references, no figures or tables
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
Terms of Use
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.


text:
Star Tracks: Monday, May 16, 2016 42 years, 2,191 covers and 55,436 stories from PEOPLE magazine's history for you to enjoy
Latest News!
- Naomi Watts and Liev Schrieber Split: Inside Their 11 Year Romance and its Sad Final Chapter
- Read the Cover Story: Brad & Angelina Split After 12 Years: It's Over
- Debate Karma: Donald Trump Mocked on Twitter for Excessive Water Drinking
- Houston Metro Officer Resigns After Video of Him Beating a Man Surfaces
- Naomi Watts Smiles on Set in NYC Amid Split from Liev Schreiber
People Top 5
LAST UPDATE: Tuesday February 10, 2015 01:10PM EST
PEOPLE Top 5 are the most-viewed stories on the site over the past three days, updated every 60 minutes
- July 07, 1986
- Vol. 26
- No. 1
As a Bombshell on Mtv Marilyn Martin Blazes Out of Her Down-Home Past
Martin's career has been on an up escalator since 1983, when she was hired as a backup singer for Stevie Nicks. That's when she traded in her faded jeans for a more upscale image, appearing onstage in beaded lace dresses that she borrowed from her flamboyant boss. Before joining Nicks, Martin sang backup with ex-Eagle Joe Walsh's band. "With Joe, I dressed like one of the guys," she says, "but with Stevie, I had to look great." Martin—all 5'2" of her—got noticed, all right. Phil Collins chose her as his partner on the smash duet Separate Lives. "Marilyn has a great voice, and I felt we had a good blend," says Collins, adding, "Also, she is very beautiful." When told to dress casually for the Separate Lives video, Martin asserted that her days of looking funky were long gone. Instead, she donned a tailored black jacket with matching tights and a T-shirt with no bra underneath.
Though Separate Lives spent four months on the Top 10, Martin was frustrated by the swampy love ballad. The video let her show off her 34-22-34 dimensions, but not her full vocal range. "People think it's Crystal Gayle singing," she says. She feels better about Night Moves, which she belts out with the power of an air raid siren. "I wanted people to know that I'm a belter as well as a balladeer," she says.
Martin's parents showed some foresight about their daughter's vampy future when they named her after Marilyn Monroe. Growing up in Tennessee and Kentucky, where her father was a miner and truck driver, Martin knew nothing about the glamorous life. But after high school she became a backup singer with a bar band, the Caldwells. Martin wearied of singing other people's hits while touring military bases and beery roadhouses for three years. "It was awful," she recalls. "Female singers had to run back to the bus to avoid the military boys."
In 1975 Martin became lead vocalist for another band, the Rhymes. To save money, she agreed to be roommates with the group's lead guitarist, Greg Droman. The arrangement was platonic. "We'd come home after our respective dates," says Martin, "and say, 'Hey, how was yours? Wait till I tell you about mine!' " Then one night, five months later, the roommates decided they were madly in love with each other. They married within a month.
After two years on the road, Marilyn and Greg settled down in Akron, Ohio, where they played local clubs. But in 1983 their quiet life ended. They won spots in Joe Walsh's band, which was touring with Nicks. When Stevie heard Martin's backup vocals, she flipped—and hired Martin for her band, too. After the tour, Marilyn and Greg moved to L.A. He got work as a recording engineer, while she sang backup on such hits as Kenny Loggins' Footloose and Tom Petty's Don't Come Around Here No More. In 1984 Atlantic Records president Doug Morris heard her in the studio with Nicks; she sent him a demo tape and he gave her a contract.
Being in demand has left Martin feeling like a vampire after sunrise. Exhausted, she reclines on her living-room sofa, trying to keep her pink-eye-shadowed lids from closing over her luminous brown eyes. "I'm beat," she says. "Between my work and Greg, I don't have time to do anything."
Martin has just finished performing in Europe and Japan and will soon complete the third video from her debut album. In the meantime her second solo video, Move Closer, has hit MTV. It should have the same effect as Night Moves, since it lets Martin model a skintight, slit-to-the-crotch, blue leather dress—all the while crooning, "Move your body real close, until we feel we're really making love." Feminist groups may find Martin's lustful image questionable, but hubby Greg, who saw his wife go from "one of the guys" to a bloodsucking vamp, takes it all with a shrug. "She's not sleazy," he reasons. "Just a bit of a ham."
- Contributors:
- Jeff Yarbrough.
More in the Archive
Today's Photos
Treat Yourself! 4 Preview Issues
The most buzzed about stars this minute!


text:
Inside the Youth Opera Council with Adina Harris
Posted 6/17/2015
Adina Harris (second from left) poses with Youth Opera Council members and soprano Ana María Martínez (second from right) at Millennium Park in September 2014 Lyric Unlimited's Youth Opera Council had a second great season. Officially launched with the 2013/14 season, the Youth Opera Council is a group of 20 high school-aged opera lovers who are dedicated to spreading the word about this fantastic art form. Among their many activities, they have weekly meetings, have conversations with Lyric staff and guest artists, and have the opportunity to attend...
Categories: Lyric Unlimited
Tags: Behind the Scenes Video Lyric Unlimited Lyric Unlimited


text:
Have any ideas for a business and wanting to make it work? The College of Business Administration at The University of Texas-Pan American in conjunction with Global Entrepreneurship Week can make that happen for you with The Great Business Idea Contest where you could win up to $1,000.
CoBA developed the contest to encourage UTPA students to generate innovative business ideas that showcase their intellect and talent. The winner of the contest and students with ideas considered meritorious will be invited to enroll in a special entrepreneurship course in the spring.
"The course will be specially designed to assist the selected students in developing their ideas into a viable, complete business plan suitable for pitching to venture capitalists or financing entities," said Dr. Penny M. Simpson, associate dean of the College of Business Administration.
The contest is open to all UTPA students who want to participate. Groups can be formed from two to five members. Participants will have the duty of writing a two- to three-page business proposal and upload a video onto YouTube with a maximum of 500 seconds.
According to Simpson, students should participate in this competition to validate their entrepreneurial ideas and make them a reality, and most of all, have fun.
Entries are due on Nov. 11. Judges will decide the winner based on the criteria of creativity, profitability, benefit to mankind, presentation quality and implementation.
Award presentations will be held at the College of Business Administration Building, Room 110 on Nov. 18 where the top three ideas will be shown and the winner will be announced, taking the $1,000 prize. Second and third place will also be rewarded with $500 and $250, respectively.
Don't miss the opportunity to participate and become an entrepreneur.
All UTPA students interested in participating in the contest will have to fill out a form online at http://coba.utpa.edu/greatbizidea2008/ and provide the basic information such as the team name, contact information and names of the group members.
For more information on the contest, visit http://coba.utpa.edu/greatbizidea2008/.
For further assistance, contact Eduardo Martinez at firstname.lastname@example.com or call (956) 381-2633.


text:
one of the most ugly soudning words you could possibly imagine
bennifer was clever
tomkat was kinda cute
but come on, brangelina? it sounds like a sound you make when you vomit.
tomkat was kinda cute
but come on, brangelina? it sounds like a sound you make when you vomit.
by kerrywithay July 03, 2006
Trending Now
Can you define these popular missing words?
Top Definition
a name made up by people that hate their own lives that they have to watch Brad Pitt and Angelina Jolie to have any satisfaction with living
Sue:Can you believe Brangelina is adopting a baby from Mauritania?
Me: Where the hell is that
Me: Where the hell is that
by Diablo45 November 02, 2006
A a stupid word created when people, with nothing better to do, see Brad Pitt and Angelina Jolie together.
"Mr. and Mrs. Smith" is a movie staring Brangelina.
by wTs June 11, 2005
Two Adults ( married )
Brad Pitt & Angelina Joile
Who Adopt about every two weeks!
Both Have Devastating Good Looks.
Brad Pitt & Angelina Joile
Who Adopt about every two weeks!
Both Have Devastating Good Looks.
Brangelina have adopted again!
by Blawhgirl1234 August 28, 2009
breakfast cereal. Brad Pitt and Angelina Jolie declare that they do not like the amalgamated name 'Brangelina' because it sounds like breakfast cereal.
Child: Mom, what's there for my breakfast?
Mom: Brangelina, my child.
Mom: Brangelina, my child.
by uttam maharjan November 02, 2010
Another dumbass "hybrid" term that the media has invented for a celebrity couple that's gonna be split up by 2008. (see also Bennifer) This one refers to Brad Pitt and Angelina Jolie.
Brangelina are gonna have a baby soon. I can hardly contain my enthusiasm! (barfs)
by The Producer January 12, 2006
Considered to be the name of the "couple Brad Pitt and Angenlia Jolie" the name is also considered a team. Team Brangelia is a group of people who support Brad and Angelina and are against Brad's soon to be ex-wife Jennifer Aniston. Her team is obviously called Team Aniston.
OMG Becky, look it's those damn Brangelina people again.
by Kaia Anastassakis August 08, 2005


text:
The names atop the list of individual point leaders this season are, for the most part, unsurprising. You've got Sidney Crosby (heard of him!), Phil Kessel (yep, he's good!), Ryan Getzlaf (oh, yeah, I watched him in Sochi), and Tyler Seguin (his breakout has been well documented, and he's even garnering some Hart Trophy buzz at this point).
As you go down the top 10, you'll come across household names like Claude Giroux, Alex Ovechkin, Patrick Kane and Corey Perry. All of these guys are bonafide superstars whose exploits result in all sorts of digital ink being spilt.
MORE: The Daily Faceoff
There's one name on that list that I've yet to mention, though. For whatever reason — and there are plenty, like the fact that he's part of a moribund franchise that's once again having a miserably underwhelming year — he's someone who doesn't seem to get talked about nearly enough. He's Kyle Okposo, and he's having himself a fantastic season as nearly everything around him burns. In some ways, this has been a long time. And in others, the campaign he's putting forth is most definitely worth talking about.
Okposo was taken No. 7 overall back in 2006 by the New York Islanders, presumably because they believed he had this sort of upside. He made a nine-game cameo as a 19-year old, putting up five points and not looking remotely out of place. The following season he was on an 82-game pace of 20-plus goals and 50 points. But he kind of seemed to level off, based on the numbers, following the promising start. There was a shoulder surgery which ate up more than half of a season, but still — it was easy to wonder whether the "Islanders stink" had ruined him.
Last season was a weird one for him. After the lockout ended and NHL play resumed, he was given the first shot at playing next to John Tavares and Matt Moulson on the top line, only to be given a quick hook after a disappointing start. He went on to finish the season with just four goals in 48 games (shooting an unsustainably low 4 percent, it should be mentioned), playing predominantly on the second line next to Frans Nielsen and Josh Bailey as we watched Brad Boyes — the guy that took over that cushy right wing gig next to Tavares — produce at a nice rate.
When the playoffs rolled around, the script seemed to flip for Okposo. He had a couple of pucks go in, and there were times when he looked like the most dominant, physically imposing player out there. With guys like Crosby, Evgeni Malkin and Tavares out there alongside him, that's no small feat. We've learned over the years not to put too much stock into small playoff sample sizes, though, because they can be misleading. The 2006-07 version of Fernando Pisani is shaking his head in agreement right now.
With that in mind, Jack Capuano once again gave him a shot next to Tavares back in October. Hadn't we seen this very script play out before?
But then something weird happened: it all clicked, and he finally reached his potential. Heck, he probably shot through his ceiling; I don't think even his biggest supporters could've anticipated this. He's currently tied with Seguin for fourth in league scoring, with 69 points. Barring some sort of injury, he'll more than likely top 30 goals for the first time in his career, and at the very least approach the 80-point plateau.
It's hard to speak to what prompted the offensive outburst. Maybe it's because he's hitting his physical peak ; finally getting long enough leash from his coach (he's second on the team in total minutes behind the departed Andrew MacDonald) probably hasn't hurt. Nor has his 63.5 percent offensive zone start percentage (easily a career high), and slightly generous on-ice shooting percentage of 11.11.
I wouldn't say it's a mirage, though. He has 10 points in nine games since the Olympic break (which is relevant, because it coincides with Tavares' season-ending injury ). Digging even further, he has managed to continue producing despite now being short his four most common linemates this season (Thomas Vanek and Moulson due to trade, Tavares and Michael Grabner with injury). He's playing on a makeshift top line with Nielsen and Anders Lee, and hasn't let that slow him down one bit.
Whether Okposo has truly found something that he'll be able to carry over remains to be seen, but for now he's one of very few things that fans on Long Island can hang their hats on in what has otherwise been another miserable season.
Dimitri Filipovic is the managing editor of Canucks Army, a Sporting News partner. Follow him on Twitter: @DimFilipovic .